User profiles for Jay H. Shubrook
 | Jay H. ShubrookProfessor, Touro University California Verified email at touro.edu Cited by 5128 |
Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease
F Kanwal, JH Shubrook, LA Adams, K Pfotenhauer… - Gastroenterology, 2021 - Elsevier
Find AGA's NASH Clinical Care Pathway App for iOS and Android mobile devices at nash.gastro.org.
Scan this QR code to be taken directly to the website.Nonalcoholic fatty liver …
Scan this QR code to be taken directly to the website.Nonalcoholic fatty liver …
Pharmacologic therapy for type 2 diabetes: synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes
…, S Leal, AS Rhinehart, JH Shubrook… - Annals of internal …, 2017 - acpjournals.org
Description: The American Diabetes Association (ADA) annually updates the Standards of
Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other …
Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other …
[HTML][HTML] Vitamin D deficiency, its role in health and disease, and current supplementation recommendations
KM Pfotenhauer, JH Shubrook - Journal of Osteopathic Medicine, 2017 - degruyter.com
Vitamin D deficiency has been identified as a common metabolic/endocrine abnormality.
Despite known dietary sources of vitamin D and the role of sunlight in its production, much of …
Despite known dietary sources of vitamin D and the role of sunlight in its production, much of …
Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American diabetes association's standards of medical care in diabetes …
…, JJ Chamberlain, JH Shubrook… - Annals of internal …, 2020 - acpjournals.org
Description: The American Diabetes Association (ADA) updates the Standards of Medical
Care in Diabetes annually to provide clinicians, patients, researchers, payers, and other …
Care in Diabetes annually to provide clinicians, patients, researchers, payers, and other …
Hypoglycemia in type 2 diabetes-more common than you think: a continuous glucose monitoring study
…, CR Marling, JH Shubrook - Journal of diabetes …, 2015 - journals.sagepub.com
Background: Hypoglycemia is often the limiting factor for intensive glucose control in
diabetes management, however its actual prevalence in type 2 diabetes (T2DM) is not well …
diabetes management, however its actual prevalence in type 2 diabetes (T2DM) is not well …
Preparing for the NASH epidemic: a call to action
F Kanwal, JH Shubrook, Z Younossi, Y Natarajan… - Metabolism, 2021 - Elsevier
… These authors disclose the following: Jay H. Shubrook has served as an advisor to Sanofi,
Eli Lilly, Novo Nordisk, Bayer, and MannKind. Elisabetta Bugianesi has served as a …
Eli Lilly, Novo Nordisk, Bayer, and MannKind. Elisabetta Bugianesi has served as a …
Cardiovascular disease and risk management: review of the American Diabetes Association Standards of Medical Care in Diabetes 2018
…, S Leal, AS Rhinehart, JH Shubrook… - Annals of internal …, 2018 - acpjournals.org
Description: The American Diabetes Association (ADA) annually updates its Standards of
Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other …
Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other …
Empagliflozin in the treatment of type 2 diabetes: evidence to date
JH Shubrook, BB Bokaie, SE Adkins - Drug design, development …, 2015 - Taylor & Francis
… Jay H Shubrook has received research support from Sanofi and has served as a consultant
to Astra Zenenca, NovoNordisk and Eli Lilly. The authors report no other conflicts of interest …
to Astra Zenenca, NovoNordisk and Eli Lilly. The authors report no other conflicts of interest …
Treatment of type 1 diabetes: synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes
…, S Leal, AS Rhinehart, JH Shubrook… - Annals of Internal …, 2017 - acpjournals.org
Description: The American Diabetes Association (ADA) annually updates Standards of Medical
Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested …
Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested …
Characterizing blood glucose variability using new metrics with continuous glucose monitoring data
Objective: Glycemic variability contributes to oxidative stress, which has been linked to the
pathogenesis of the long-term complications of diabetes. Currently, the best metric for …
pathogenesis of the long-term complications of diabetes. Currently, the best metric for …